The purpose of this study was to evaluate the influence of busulfan (BU) pharmacokinetics on survival, grades II-IV acute graft-versus-host disease (GVHD), nonrelapse mortality (NRM) and relapse in a group composed of 45 children (Ͻ18 years) and seven adults with acute myeloid leukemia (AML) in first complete remission and undergoing hematopoietic stem cell transplantation (SCT). Fifty-two patients underwent autologous (n ‫؍‬ 25) or allogeneic (n ‫؍‬ 27) SCT. The median age was 8.9 years (range 0.6-53 years). Conditioning therapy consisted of BU and cyclophosphamide. Improved disease-free survival was found in those patients with a steady-state concentration of BU (CssBU) below the median (Ͻ578 mg/ml, P ‫؍‬ 0.05), and the same trend was noted for overall survival (P ‫؍‬ 0.07). This was secondary to a higher incidence of NRM in the group of patients with CssBU above the median (P ‫؍‬ 0.06). There was no significant correlation with CssBU and relapse (P ‫؍‬ 0.31). No association between CssBU and GVHD was found in allogeneic patients (P ‫؍‬ 0.30). Relapse was evaluated among the subgroups of age (Ͻ or Ͼ10 years) and transplant type (allogeneic or autologous) with no statistically significant association observed among these factors. Multiple regression analysis for relapse revealed no significant correlation with CssBU above or below the median, age, or transplant type. In this study, CssBU below the median did not correlate with an inferior outcome for patients with AML. Pharmacokinetic dosing of BU may be important for prevention of NRM but does not appear to influence the risk of relapse in this largely pediatric population with AML. Bone Marrow Transplantation (2000) 26, 607-614. Keywords: busulfan; pharmacokinetics; acute myelogenous leukemia Busulfan (BU) is a primary myeloablative agent for use in non-total body irradiation-containing preparative regimens during both autologous and allogeneic stem cell transplan- tation (SCT) for acute or chronic leukemia and for nonmalignant disorders 1-3 (hemoglobinopathies, immunodeficiencies, and inborn errors of metabolism). Since first used in SCT, investigators have studied the pharmacokinetic properties of BU and attempted to determine the optimal dose and administration schedule for this drug. 4 It has been determined that BU pharmacokinetic parameters do differ between children and adults. 5 However, attempts to correlate this data with engraftment, toxicity, or relapse have not led to definitive or consistent findings.
tation (SCT) for acute or chronic leukemia and for nonmalignant disorders [1] [2] [3] (hemoglobinopathies, immunodeficiencies, and inborn errors of metabolism). Since first used in SCT, investigators have studied the pharmacokinetic properties of BU and attempted to determine the optimal dose and administration schedule for this drug. 4 It has been determined that BU pharmacokinetic parameters do differ between children and adults. 5 However, attempts to correlate this data with engraftment, toxicity, or relapse have not led to definitive or consistent findings.
Children have been found to have consistently lower peak BU concentrations, higher rates of drug clearance, higher volumes of distribution, and lower area-under-thecurve (AUC) concentrations than adults. [5] [6] [7] These BU pharmacokinetic parameters are influenced by the underlying disease, age, circadian rhythms, disease stage and drug interactions. 4, [8] [9] [10] [11] [12] [13] [14] Subsequently, some investigators have recommended that children be dosed with BU based upon body surface area (37.5-40 mg/m 2 /dose, total dose 600-640 mg/m 2 ) [15] [16] [17] [18] rather than the standard per kilogram dosing (1 mg/kg/dose every 6 h, total dose 16 mg/kg) 19, 20 utilized for most adult BU-containing preparative regimens. This has been shown to produce BU levels in children which are comparable to those obtained in adults, prompting some institutions to adjust BU doses based upon first dose pharmacokinetic studies in order to achieve desired levels. 15, 21, 22 Attempts to increase plasma BU concentrations have been supported primarily by reports of predisposition to graft rejection with BU steady-state concentration (CssBU) levels Ͻ200 ng/ml 23 as well as by the finding that lower CssBU levels were associated with a higher risk of relapse in patients with chronic myeloid leukemia. 24 This approach must be taken with caution, however, as there are also data suggesting that there is increased regimen-related toxicity (primarily veno-occlusive disease) 23, [25] [26] [27] and higher transplant-related mortality (TRM) in allogeneic SCT patients who achieve high BU levels as well data that BU neurotoxicity is dose dependent. 28 The purpose of this study was to evaluate the influence of BU pharmacokinetics on relapse and non-relapse mortality, survival, and grades II-IV acute graft-versus-host disease (GVHD), in a population composed primarily of children with acute myeloid leukemia (AML) in first complete remission.
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Patients and methods
Patients
Fifty-two patients underwent autologous (n = 25) or allogeneic (n = 27) stem cell transplantation from fully matched sibling donors, for AML in first complete remission ( Table  1 ). The median age at time of transplant was 8.9 years with a range of 0.6 to 53 years. Fifty-six percent were male. All patients or their guardians signed consents which had been approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota, or by the Human Subjects' committees of the participating institutions.
Pretransplant conditioning therapy
All patients underwent conditioning therapy consisting of busulfan and cyclophosphamide. BU was administered at doses of 1 mg/kg/dose p.o. every 6 h for 16 doses (n = 47), 2 mg/kg/dose p.o. every 12 h for 8 doses (n = 4) or 1.25 mg/kg/dose p.o. every 6 h for 16 doses (n = 1). Cyclophosphamide was given at doses of either 50 mg/kg/dose × 4 (or 1500 mg/m 2 /dose × 4), (n = 46), or 60 mg/kg/dose × 2, (n = 6). Medication for seizure prophylaxis was not routinely provided to all patients.
Supportive care
Patients were hospitalized in private rooms with highefficiency particulate air filtration. Antibiotic prophylaxis with trimethoprim-sulfamethoxazole was administered before the development of fever. At the onset of fever, patients received empiric broad-spectrum anti-bacterial and anti-fungal agents. Those patients seronegative for cytomegalovirus (CMV) received blood products from seronegative donors, or blood products were filtered to remove contaminating leukocytes. Patients seropositive for CMV or herpes simplex virus received acyclovir prophylaxis.
Graft-versus-host disease
GVHD was diagnosed and graded by standard criteria. 29, 30 GVHD prophylaxis in the 27 allogeneic recipients consisted of cyclosporin and methotrexate (n = 8), methotrexate alone (n = 14), or other regimens in five patients.
BU pharmacokinetics
Patient specimens were collected for analysis at the following times after the first dose of oral busulfan: 0, 30, 60, 90, 120, 180, 360 min. BU pharmacokinetic studies were performed at the University of Minnesota by a high-phase liquid chromatography assay that has previously been described. 31 No adjustments to administered doses were made based upon pharmacokinetic parameters.
Pharmacokinetic modeling
Pharmacokinetic parameters were estimated by an iterative computer program to fit a first-order one-compartment model (MK Model; Biosoft, Milltown, NJ, USA). Utilizing the raw data, the following parameters were estimated from the model: clearance (Cl, 1/min/kg); volume of distribution (VD, 1/kg); and absorption rate constant (Ka). From these estimates, the following parameters were then derived: absorption half-life (ab t 1/2 , min) and elimination half-life (el t 1/2 , h). Estimates of the plasma concentrations for each time point are derived from Cl, VD and Ka. The following parameters were determined from the derived plasma concentration-time curve: area under the concentration-time curve (AUC, m*min), steady-state concentration (Css, ng/ml), maximum concentration (Cmax, m); and minimum concentration (Cmin, m). For direct comparison between groups, the AUC, Cmax and Cmin were normalized to a dose of 1 mg/kg by dividing the actual value by the dose administered.
Statistical methods
In order to compare the distribution of patient and transplant characteristics as well as pharmacokinetic parameters across transplant centers, Pearson's chi-square test was employed for categorical variables and the general Wilcoxon test was used for continuous variables. When appropriate, Fisher's exact test was used.
Study endpoints included relapse, survival, disease-free survival, non-relapse mortality and acute GVHD. Estimates of the endpoints were calculated by the Kaplan-Meier method. 32 In the calculation of relapse, patients were censored at date of death or last contact. For non-relapse mortality (NRM), patients were censored at the date of first relapse or last contact. Statistical comparisons of the Kaplan-Meier curves were completed by use of the logrank test. Due to the limited sample size, CssBU was first evaluated by quartiles and then categorized into groups above and below the median.
In order to control for possible confounding, the relationship between relapse and CssBU was first evaluated within subgroups of age and type of transplant and then included in Cox proportional-hazards' models.
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Results
Patient characteristics
Presented in Table 1 are the patient characteristics of the study population. Patients were stratified by the center in which the transplant was performed (University of Minnesota vs outside center) and data are presented by center, as well as for the group as a whole. Most patients in this cohort were children (86%), with a median age of 8.9 years, seven of 52 patients (14%) were adults (age у18 years) ( Table 2) .
BU levels
Complete BU pharmacokinetic data are presented in Table  2 . There was no difference in these parameters when stratified by transplant center. The median CssBU was 578 ng/ml, the median AUC 846 m*min, and the median Bone Marrow Transplantation clearance 0.005 l/min/kg. All BU pharmacokinetic parameters were also analyzed by age Ͻ10 years, 10-17 years, and у18 years. Not surprisingly, there was a marked variation between children and adults (у18 years) in all pharmacokinetic parameters with children (either Ͻ10 years or 10-17 years) having lower CssBU, Cmin, Cmax, absorption, and AUC. They also had higher rates of clearance and larger volumes of distribution than adults.
Relapse and non-relapse mortality
Relapse and non-relapse mortality were evaluated for each BU pharmacokinetic parameter (Table 3 ). Outcomes were evaluated by stratifying at the median steady-state concentration of BU (CssBU) which was 578 ng/ml. No correlation was found with the probability of relapse and the CssBU (Figure 1 ) or with any other pharmacokinetic parameter. A trend towards a higher risk of non-relapse mortality was found for CssBU above the median (24% vs 4% at 1 year, 30% vs 8% at 3 years, P = 0.06, Figure 2 ), as well as for Cmin above the median (21% vs 8% at 1 year, 33% vs 13% at 3 years, P = 0.06). Non-relapse mortality occurred in eight allogeneic and three autologous patients. In allogeneic patients, seven deaths were from GVHD (four acute and three chronic, all but two had CssBU above the median); one death was from veno-occlusive disease of the liver. In autologous patients, two deaths were from infection and in one the cause was unknown.
In further univariate analysis, relapse was evaluated among the subgroups of age (Ͻ or у10 years), transplant type (allogeneic or autologous), time from diagnosis to transplant (Ͻ or у to median), gender, and acute GVHD status (time dependent). Relapse by CssBU for allogeneic patients was no different for BU levels above the median (n = 16) or below the median (n = 11, P = 0.12). Similarly, relapse by CssBU for autologous patients was no different for BU levels above (n = 10) or below (n = 15) the median (P = 0.73). Although age Ͻ10 correlated with BU levels below the median (Table 2) , this did not change the lack of association between relapse rate and CssBU above or below the median for both allogeneic (P = 0.27) and autologous patients (P = 0.44). Additionally, no association was found for the time from diagnosis to transplant, gender, or acute GVHD status with the risk of relapse.
Multiple regression analysis was also performed to investigate any effect of these factors on the risk of relapse. As shown in Table 4 , there was no significant correlation with CssBU above or below the median, age as a continuous variable, or transplant type.
Survival
Both survival and DFS were analyzed with respect to CssBU (Table 5) . Patients with CssBU below the median were found to have a superior DFS to those with CssBU above the median (73% vs 54% at 1 year, 63% vs 42% at 3 years, P = 0.05, Figure 3 ). This same trend was noted for survival but did not reach statistical significance (P = 0.07). A comparison of the other pharmacokinetic parameters with DFS found improved survival with Cmin BU below the median (P = 0.02), and with BU clearance which was higher than the median (P = 0.05).
GVHD
For the allogeneic patients (n = 27), there was a 30% risk of acute GVHD at 100 days, but no association between CssBU and grades II-IV acute GVHD was found (P = 0.30).
Discussion
This study is one of the largest series of a single disease in a relatively young patient population in which BU pharmacokinetics have been studied. Our primary goal was to correlate BU levels with the risk of relapse in patients with AML as this has not been reported previously. We found no significant correlation between risk of relapse and BU levels, particularly with CssBU levels which were below the median value. Our median CssBU was 578 ng/ml which is significantly lower than that reported by Slattery et al, 24 where relapse was associated with CssBU levels Ͻ917 ng/ml in a group of adult patients with CML. While our median levels were substantially lower than this, several factors may explain this finding. First, it has been well documented that the CssBU and AUC with standard oral dosing of BU are lower in children than in adults. The youngest CML patient was 24 years old with a range of 24-57 (median not given), the median age of our patient population was 8.9 years, and as demonstrated in Table 2 , all our pharmacokinetic parameters were age dependent. Thus, it is not surprising that the median CssBU level was lower in our study. Despite this, however, patients with higher CssBU levels in our study did not have an improved DFS or a lower risk of relapse. The exact reason for this, whether it be diseasespecific chemosensitivity, patient age or other factors, can not be determined from this study.
Although we did not find a correlation between CssBU and grades II-IV aGVHD, the majority of non-relapse mortality seen in allogeneic patients was a consequence of acute or chronic GVHD. The incidence of GVHD was also evaluated by Slattery et al, 24 and they similarly did not find a correlation between acute or chronic GVHD and CssBU levels above or below the median. In at least five of the eight deaths in their study, GVHD was either the primary cause of death or likely to be a contributing factor. Further investigation into the possible influence of BU levels on the development of GVHD will need to be performed in larger prospective studies.
We did find a correlation with poorer DFS in patients with CssBU or Cmin greater than the median, and BU clearance below the median. Detailed analysis of relapse and non-relapse mortality revealed a higher incidence of non-relapse mortality in patients with CssBU or Cmin which were higher than the median. A similar finding has been reported by Ljungman et al, 27 where in a group of patients with acute and chronic leukemias and myelodysplastic syndrome, increased transplant-related mortality (TRM) was seen with BU levels in the highest quartiles. This translated into lower DFS and survival compared to other patients. In this analysis, age did not influence TRM when analyzed as a continuous variable or grouped above and below 10 years of age. Similar to our data, these investigators also found no association between BU concentration and relapse.
Based upon these findings, accepting a potentially greater risk of toxicity from higher BU doses (such as those delivered on a per meter-squared calculation) for patients with AML may not be beneficial as it may carry with it a higher risk of toxicity without decreasing the risk of relapse. How-611 Table 3 Relapse and non-relapse mortality Bone Marrow Transplantation ever, this conclusion may only be valid for patient populations which are composed primarily of the pediatric age group. We also recognize that this study population contained some heterogeneity given that there were both autologous and allogeneic transplants, and that four patients received BU on an every 12 h schedule rather than every 6 h (same total dose), and six patients received cyclophosphamide to a total dose of 120 mg/kg compared to 200 mg/kg which most patients were given. Additionally, this study was limited to a first dose pharmacokinetic analysis and we acknowledge the fact that variability, both intraand interpatient, exists with subsequent doses of oral BU. In 56% of patients, BU levels were also obtained after the 10th dose. From the available data, the mean CssBU and AUC from the first and 10th doses were not significantly different (data not shown). Other investigators have reported that repeated doses over 4 days did not modify Table 4 Multiple regression analysis on relapse BU kinetics or lead to accumulation of the drug and that the mean values of the Cmax and half-life after the first and last dose were very similar. 5 Other studies have also found that there was a significant correlation between the AUC of the first and subsequent BU doses. 16, 17 Additionally, a previously reported study performed in our laboratory determined that a comparison of first and 10th dose kinetics was similar, being within 20% of each other most (90%) of the time. 31 Nonetheless, we cannot exclude the fact that there may be a correlation between BU pharmacokinetics and outcome if doses subsequent to the first had been analyzed in the entire group of patients. Future prospective studies in larger numbers of patients will be required to examine this relationship. In a recent analysis of preparative regimens in transplants for children with acute lymphoblastic leukemia, compared to total body irradiation (TBI), the use of BU was associated with a higher risk of treatment-related mortality and inferior leukemia-free survival. 34 These regimens have been compared in AML without a clear advantage to TBI being detected, and with BU offering the advantage in children of fewer late effects such as growth delay, gonadal dysfunction, thyroid dysfunction and cataracts. [35] [36] [37] With the availability of intravenous BU (Busulfex; Orphan Medical, Minnetonka, MN, USA) many investigators are now evaluating whether this formulation will provide more consistent pharmacokinetic parameters, which may improve on the safety and efficacy of BU administration during SCT. Definitive studies remain to be published, although data that have been presented in abstract form would suggest that intravenous BU reduces inter-patient and inter-dose variability and reduces the incidence of VOD. [38] [39] [40] In children, the use of intravenous BU would eliminate the frequent need for administration via nasogastric tube as well as the problem of oral bioavailability, particularly in infants and small children. [5] [6] [7] Definitive studies comparing the oral and intravenous forms of BU will be necessary in order to determine whether the safety and pharmacokinetic profile of intravenous BU will be such that it should replace oral BU in transplant preparative regimens.
Despite a sizeable amount of literature on BU pharmacokinetics there remain many questions without a definitive answer. The primary concerns for inadequate BU levels are the risks of rejection and at least for CML, the risk of relapse. High levels may carry the risk of increased toxicity. Several studies have determined that higher BU dosing (600-640 mg/m 2 total dose) can overcome the age-dependent differences in BU pharmacokinetics in the autologous or allogeneic setting for malignancies, 16, 17 and in the allogeneic setting in patients with thalassemia. 18 While these studies did not find a higher incidence of regimen-related toxicity, they all fail to show whether exposure of patients to higher BU doses has any impact upon engraftment, survival or DFS. Another study in thalassemia 31 failed to find any correlation with the plasma pharmacokinetics of BU and the transplant toxicity or outcome (engraftment delay or rejection, aplasia, mixed chimerism, or mortality) of allogeneic transplant recipients. There may also be some interaction based upon the dose of cyclophosphamide utilized in different protocols (200 mg/kg vs 120 mg/kg). There were not large enough numbers in the present study to address this point. We conclude that BU pharmacokinetic monitoring in the setting of SCT for AML, particularly in children, does not appear to be useful in predicting relapse, although it may be useful to monitor patients for high BU concentrations that may be associated with a higher risk of TRM. However, we acknowledge the fact that in this study the overall number of subjects was relatively small, and we did not control for other prognostic variables such as presenting white blood cell count and type of induction chemotherapy that was administered as these factors may also have an impact on relapse. It appears from our studies and those reported in the literature that the importance (or not) of BU pharmacokinetics is age-, disease-, and regimenrelated. Additional studies in adults with AML will be Bone Marrow Transplantation necessary to define the role of BU pharmacokinetics in that age group.
